The Good Men Project

FDA Approves Breakthrough Pancreatic Cancer Drug – An Oncologist Explains How Daraxonrasib Nearly Doubles Survival

The FDA’s approval of daraxonrasib marks a significant development in pancreatic cancer treatment, with clinical trial ...
MedPage Today on MSN

FDA Approves First Treatment for Rare Thyroid Hormone Disorder

Tiratricol is indicated for patients with MCT8 deficiency ...

AstraZeneca files for US FDA approval of HUTCHMED lung cancer drug combination

Sept 29 (Reuters) - HUTCHMED (China) said on Tuesday that Anglo-Swedish drugmaker AstraZeneca had applied to the US Food and ...
CURE

Hot Flashes From Breast Cancer Treatment May Soon Have an FDA-Approved Fix

Because most women with HR-positive breast cancer are advised to avoid hormone therapy, a nonhormonal option matters. The FDA ...

Rejoni Receives FDA Approval of the Juveena® Hydrogel System to Reduce Intrauterine Adhesions Following Hysteroscopic Adhesiolysis

Approval supported by a multicenter, randomized, subject- and evaluator-blinded pivotal study BEDFORD, Mass.--(BUSINESS WIRE)--September 29, 2026-- ...
Medscape

FDA Approval of Ameluz Seen as Boon to Skin Cancer Armamentarium

The agency’s backing could potentially increase the use of this first-to-be-approved nonsurgical PDT option in treating basal ...
Healio

FDA approves Olumiant for teens with severe alopecia

The FDA approved an expanded indication for baricitinib, a once daily oral JAK inhibitor, for teens aged 12 and older with ...

Teva Reports FDA Approval for Degevma

Teva Pharmaceutical Industries (TEVA) said late Monday the US Food and Drug Administration has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention of bone complications ...

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages

How much of a cancer drug is too much? Patients, researchers challenge FDA-approved dosages Northwestern University economist ...
Cancer Network

Lirafugratinib Approval Adds a Third FGFR2 Inhibitor in Cholangiocarcinoma

Chih-Yi “Andy” Liao, MD, discusses the FDA approval of lirafugratinib and what the field has learned about resistance to FGFR2 inhibitors.